News | July 02, 2024
Merck and Orion announce option providing Merck global exclusive rights to Opevesostat
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
Mahatma Gandhi Cancer Hospital & Research Institute has emerged as the leading provider of comprehensive cancer care in Viza
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Lenire is the first and only bimodal neuromodulation device to be awarded a Federal Supply Schedule (FSS) Contract from the US Government
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Azilsartan Medoxomil and Chlorthalidone Tablets had annual sales of US$ 77.9 mn in the United States (IQVIA MAT March 24).
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
Glenmark's current portfolio consists of 197 products authorized for distribution in the U.S. marketplace
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Subscribe To Our Newsletter & Stay Updated
